Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5285079 | 0.88 | CCR3 (0.45) | CCR3F10SLC6A5NPY5R | |
| SCHEMBL5285712 | 0.81 | MEN1 (0.51) | CCR3HTR2A | |
| SCHEMBL5282768 | 0.81 | HRH2 (0.41) | F10SLC6A5 | |
| SCHEMBL6038175 | 0.80 | ADRA1A (0.46) | CCR3DRD2MCHR1HTR7 | |
| SCHEMBL5277819 | 0.79 | HRH2 (0.69) | — | |
| SCHEMBL5291389 | 0.79 | HRH2 (0.58) | — | |
| SCHEMBL5278692 | 0.79 | HRH2 (0.53) | CCR3HTR2A | |
| SCHEMBL5290421 | 0.79 | HRH2 (0.53) | — | |
| SCHEMBL5282761 | 0.79 | HRH2 (0.41) | F10 | |
| SCHEMBL5293720 | 0.75 | L3MBTL1 (0.58) | DRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | CCR3 3790/4885DRD2 2860/4885DRD4 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.